Our partner Signos has raised $20 million in new funding and expanded its partnership with Dexcom as it continues to grow its AI-powered weight management platform. The company, whose FDA-cleared system combines continuous glucose monitoring with personalized AI-driven guidance, plans to use the funding to enhance predictive features and expand adoption across the rapidly growing metabolic health market.
The announcement also includes a new distribution agreement that will make Signos available through Dexcom’s direct-to-consumer channel. As demand for GLP-1 therapies and personalized health solutions continues to rise, Signos is positioning itself at the intersection of glucose monitoring, behavioral coaching, and AI-powered health insights.